Cervical Cancer Clinical Trial
Official title:
Improving Cervical Cancer Prevention Among HIV-Infected Women Using Novel HPV Based Biomarker Assays
Background:
- Cervical cancer is a major cause of cancer deaths among women. Most cases of cervical
cancer are caused by the human papillomavirus (HPV). HPV is more common in women who
have the human immunodeficiency virus (HIV). India has one of the highest rates of women
who have both cervical cancer and HIV infection.
- Cervical cancer can be discovered in early stages by screening for HPV infection.
Researchers want to compare new cervical cancer screening tests for HIV-infected women.
They also want to know more about how HPV can lead to cervical cancer in HIV-infected
women. To do so, they will hold a study to screen HIV-infected women in India.
Objectives:
- To improve cervical cancer screening methods in HIV-infected women in India.
Eligibility:
- Women at least 18 years of age who have HIV infection.
- Participants will be recruited from HIV-focused health care clinics in Pune and Chennai,
India.
Design:
- Participants will have a physical exam and medical history. They will provide a urine
sample and proof of HIV infection.
- Participants will have a gynecological exam. This will involve a pelvic exam and Pap
smear to collect cells for study. It will also involve a cervical exam to look for
precancerous cells. Cervical tissue may be collected.
- Participants will also provide a blood sample for testing.
- Participants will return in 2 weeks for the test results. If there are signs of
precancerous or cancer cells, participants will be referred to a doctor for treatment.
Background:
While HPV DNA testing is a highly sensitive screening method for cervical cancer, it cannot
differentiate between the majority of benign infections and few persistent infections linked
to cervical precancer. Given the high prevalence of carcinogenic HPV DNA and higher risk for
cervical precancer and cancer among HIV-infected women, there is a substantial need for
screening tests that are both adequately sensitive as well as specific, so as to maximize
detection while reducing false-positive referrals. Furthermore, the unique immunological
milieu in HIV-infected women presents significant opportunities to study natural history of
HPV-mediated cervical oncogenic process in the context of immunosuppression.
Objectives and Methods:
The primary objective is to evaluate the clinical performance of two novel biomarker assays
for detection of histologically-confirmed cervical intraepithelial neoplasia grade 2/3 or
more severe (greater than or equal to CIN2 and greater than or equal to CIN3) among
HIV-infected women. These tests include: (i) immunocytostaining by p16(INK4a)/Ki-67
(biomarkers correlated with the oncogenic transformation of cervical cells following
persistent carcinogenic HPV infection) and (ii) testing for HPV E6/E7 mRNA (expressed during
progression of a transient to a transforming HPV infection). Secondary objectives include
studying the association of risk factors and biomarkers with specific HPV genotypes and
studying the interaction of HIV and HPV in cervical disease categories and in the context of
immunosuppression.
Eligibility:
HIV-infected women, 18 years or older, with no history of previous treatment for cervical
precancer/cancer, not currently pregnant, and able to provide informed consent.
Design:
This cross sectional study will be conducted in collaboration with Indian Council of Medical
Research (ICMR), in three institutions, with substantial experience in conduct of clinical
research on HIV/AIDS and HPV/cervical cancer: the National AIDS Research Institute (NARI) in
Pune, the National Institute of Epidemiology (NIE) in Chennai, and the Jawaharlal Nehru
Medical College (JNMC) in Belgaum. A total of 1000 HIV-infected women attending HIV care and
treatment clinics in Pune (n=400) and Chennai (n=400), and Belgaum (n=200) will be recruited.
According to routine practice, participants will undergo per-speculum examination and
cervical specimen collection, followed by a detailed diagnostic colposcopy exam with biopsies
as indicated for histological analysis. Cervical specimens will be used for liquid-based
cytology as well as simultaneous independent assessment with p16(INK4a)/Ki-67 and HPV E6/E7
mRNA testing. HPV DNA genotyping will be conducted by Linear Array HPV polymerase chain
reaction. We will estimate the clinical performance (sensitivity, specificity, positive and
negative predictive values, Youden s Index, and positive and negative likelihood ratios with
95% confidence intervals) of individual tests and combinations for prevalent detection of
histologically-confirmed greater than or equal to CIN2 and greater than or equal to CIN3
among HIV-infected women. Additionally we will estimate age-specific and disease-specific HPV
prevalence rates and HPV genotype composition, examine factors associated with greater than
or equal to CIN2/greater than or equal to CIN3 lesions, examine the relationships of
biomarker positivity at the HPV genotype-specific level, and evaluate the role of
immunosuppression on HPV-mediated carcinogenesis. This study will permit validation of
collection, transport, storage, and implementation protocols, allow evaluation of the field
adoption and efficacy of these newer assays, describe the sensitivity and specificity of any
of the tests or combinations with reasonable precision for a wide range of prevalence of
greater than or equal to CIN3, and provide a resource for studies of HIV-HPV coinfection.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |